CL Labs INC.

CL Labs INC. was paid $10.96M by Medicaid between Jul 2022 and Aug 2024, across 6 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 56% of everything it billed.

33Billing provider infoCL LABS INC.
CHICAGO, IL 60646

33aNPI1184379778assigned 02/14/2022

33bProvider typeClinical Medical Laboratory

28Total paid$10.96M

24GClaims248,376

24DCodes billed6

24AFirst – last monthJul 2022 – Aug 2024

Compared with peers

Next to other Clinical Medical Laboratory providers in Illinois

Rank by total paid#14 of 235

Median peer was paid$123K

This provider vs. median89×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2022	179,358	$7.44M
2023	63,290	$2.83M
2024incomplete	5,728	$685K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	56%	81,675	21,363	$6.10M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	18%	82,441	21,387	$1.92M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	17%	73,992	21,347	$1.84M
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	9.1%	7,957	3,845	$994K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	2,299	967	$109K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	0%	12	12	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLEVY, CHARLES (PRESIDENT)

Same official

Other billing entities under LEVY, CHARLES

Full network →

Provider	Location	Paid
Sentra Laboratories INC/	Bay Shore, NY	$510K
S & T Medical Group LTD	Hoffman Estates, IL	$0.00

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.